Fate Therapeutics FATE Stock
Fate Therapeutics Price Chart
Fate Therapeutics FATE Financial and Trading Overview
| Fate Therapeutics stock price | 1.35 USD |
| Previous Close | 1.15 USD |
| Open | 1.18 USD |
| Bid | 1.11 USD x 1200 |
| Ask | 1.16 USD x 1200 |
| Day's Range | 1.13 - 1.19 USD |
| 52 Week Range | 0.66 - 5.92 USD |
| Volume | 976.87K USD |
| Avg. Volume | 1.82M USD |
| Market Cap | 129.54M USD |
| Beta (5Y Monthly) | 2.231 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.46 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.69 USD |
FATE Valuation Measures
| Enterprise Value | -28704016 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.67261904 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 9.713932 |
| Price/Book (mrq) | 0.44894716 |
| Enterprise Value/Revenue | -2.153 |
| Enterprise Value/EBITDA | 0.171 |
Trading Information
Fate Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.231 |
| 52-Week Change | -75.21% |
| S&P500 52-Week Change | 13.16% |
| 52 Week High | 5.92 USD |
| 52 Week Low | 0.66 USD |
| 50-Day Moving Average | 1.2 USD |
| 200-Day Moving Average | 1.63 USD |
FATE Share Statistics
| Avg. Volume (3 month) | 1.82M USD |
| Avg. Daily Volume (10-Days) | 1.15M USD |
| Shares Outstanding | 114.63M |
| Float | 92.33M |
| Short Ratio | 4.62 |
| % Held by Insiders | 1.73% |
| % Held by Institutions | 94.12% |
| Shares Short | 9.51M |
| Short % of Float | 9.47% |
| Short % of Shares Outstanding | 8.30% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | March 31, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2534.069% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -23.97% |
| Return on Equity (ttm) | -49.23% |
Income Statement
| Revenue (ttm) | 13.34M USD |
| Revenue Per Share (ttm) | 0.11 USD |
| Quarterly Revenue Growth (yoy) | -15.40% |
| Gross Profit (ttm) | -102194000 USD |
| EBITDA | -168276992 USD |
| Net Income Avi to Common (ttm) | -175879008 USD |
| Diluted EPS (ttm) | -1.49 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 240.42M USD |
| Total Cash Per Share (mrq) | 2.1 USD |
| Total Debt (mrq) | 83.33M USD |
| Total Debt/Equity (mrq) | 28.89 USD |
| Current Ratio (mrq) | 8.815 |
| Book Value Per Share (mrq) | 2.517 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -123333000 USD |
| Levered Free Cash Flow (ttm) | -76877376 USD |
Profile of Fate Therapeutics
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 12278 Scripps Summit Drive |
| ZIP | 92131 |
| Phone | 858 875 1800 |
| Website | https://www.fatetherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 181 |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Q&A For Fate Therapeutics Stock
What is a current FATE stock price?
Fate Therapeutics FATE stock price today per share is 1.35 USD.
How to purchase Fate Therapeutics stock?
You can buy FATE shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Fate Therapeutics?
The stock symbol or ticker of Fate Therapeutics is FATE.
Which industry does the Fate Therapeutics company belong to?
The Fate Therapeutics industry is Biotechnology.
How many shares does Fate Therapeutics have in circulation?
The max supply of Fate Therapeutics shares is 115.33M.
What is Fate Therapeutics Price to Earnings Ratio (PE Ratio)?
Fate Therapeutics PE Ratio is now.
What was Fate Therapeutics earnings per share over the trailing 12 months (TTM)?
Fate Therapeutics EPS is -1.46 USD over the trailing 12 months.
Which sector does the Fate Therapeutics company belong to?
The Fate Therapeutics sector is Healthcare.
Fate Therapeutics FATE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23724.96 USD — |
+0.61
|
9.88B USD — | 23628.82 USD — | 23946.23 USD — | — - | 9.88B USD — |
| US Tech US 700 Small Cap Index NQUS700SC | 2566.34 USD — |
+0.47
|
— — | 2546.3 USD — | 2571.79 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 29137.78 USD — |
+0.62
|
— — | 29019.72 USD — | 29409.52 USD — | — - | — — |
| US Tech Global Market Composite NQGM | 2309.83 USD — |
+1.58
|
— — | 2282.44 USD — | 2312.75 USD — | — - | — — |
| US Tech Biotechnology NBI | 5366.46 USD — |
+1.2
|
— — | 5276.16 USD — | 5372.71 USD — | — - | — — |
| US Tech Health Care IXHC | 1115.96 USD — |
+0.87
|
— — | 1099.74 USD — | 1117.62 USD — | — - | — — |
- {{ link.label }} {{link}}